Get a full analysis report for any ticker →

Analyst Ratings & Price Targets

Analyst upgrades, downgrades, and price target changes for US stocks. Track Wall Street consensus shifts and rating actions across mid and large-cap equities.

BBWIAnalysis

Bath & Body Works: Analyst Price Target Disagreement Signals Uncertain Recovery

Bath & Body Works reported Q1 EPS of $2.05 against a $1.77 consensus estimate, triggering a stock pop that subsequently faded amid a CFO transition and a persistent revenue decline. At 6.1x forward earnings and a 20%-plus FCF yield, BBWI looks deeply discounted, but CEO Daniel Heaf's admission of brand underperformance and unresolved leadership uncertainty keep the risk/reward genuinely balanced.

HBMAnalysis

TSX Approves Hudbay 5% Buyback; Barclays Goes Overweight

Hudbay Minerals secured TSX approval to repurchase up to 5% of its outstanding shares while Barclays initiated coverage with an Overweight rating, supported by 27.3% revenue growth and $546M in trailing free cash flow. The bull case is coherent at a medium confidence level, but GuruFocus values the stock at $9.84 against a $31.87 trading price and the consensus analyst target implies near-zero upside from current levels.

SEDGAnalysis

SolarEdge Q1 Results Spark Rally Above Analyst Target

SolarEdge Technologies shares trade at $61.76, some 56% above the analyst consensus price target of $39.57, after Q2 profitability guidance sparked a post-earnings rally despite a Q1 EPS miss. Three consecutive quarters of narrowing losses and free cash flow of $278 million frame the turnaround case, while the 90-day insider record shows selling near analyst-target price levels with no open-market buying on record.

JBLUAnalysis

JetBlue Is Losing $1.2 Billion a Year But Trading Above Every Analyst Target — The Takeover Explains Why

JetBlue is granting United Airlines physical gate access at JFK's Terminal 6 and enabling cross-network booking with cash or points, mirroring the operational integration playbook airlines run before acquisitions. The stock trades at $5.60 versus a $4.49 consensus target because analysts are modeling a standalone turnaround while the market is pricing takeover optionality that the accelerating Blue Sky partnership makes more plausible by the quarter.